In vivo DCA treatment (2g/L, ad libitum) significantly reduces CD4+ T cell accumulation, especially Th17 cells, in the spleen and mesenteric lymph nodes in a naive T cell adoptive transfer colitis model (48). Here, CD4 is linked to colitis.